Page 172 - 南京医科大学学报自然科学版

第41卷第7期
·1102 · 南 京 医 科 大 学 学 报 2021年7月

2541 11950-11954
［29］ VAN DEN BRINK E N，TER MEULEN J，COX F，et al. ［41］ VOLZ A，KUPKE A，SONG F，et al. Protective efficacy of
Molecular and biological characterization of human mono⁃ recombinant modified vaccinia virus Ankara delivering
clonal antibodies binding to the spike and nucleocapsid Middle East respiratory syndrome coronavirus spike glyco⁃
proteins of severe acute respiratory syndrome coronavirus protein［J］. J Virol，2015，89（16）：8651-8656
［J］. J Virol，2005，79（3）：1635-1644 ［42］ HAAGMANS B L，VAN DEN BRAND J M，RAJ V S，et
［30］ TER MEULEN J，VAN DEN BRINK E N，POON L L，et al. An orthopoxvirus⁃based vaccine reduces virus excre⁃
al. Human monoclonal antibody combination against tion after MERS⁃CoV infection in dromedary camels［J］.
SARS coronavirus：synergy and coverage of escape mu⁃ Science，2016，351（6268）：77-81
tants［J］. PLoS Med，2006，3（7）：e237 ［43］ WANG L，SHI W，JOYCE M G，et al. Evaluation of candi⁃
［31］ ZHU Z，CHAKRABORTI S，HE Y，et al. Potent cross⁃re⁃ date vaccine approaches for MERS ⁃ CoV［J］. Nat Com⁃
active neutralization of SARS coronavirus isolates by hu⁃ mun，2015，6：7712
man monoclonal antibodies［J］. Proc Natl Acad Sci USA， ［44］ MUTHUMANI K，FALZARANO D，REUSCHEL E L，et
2007，104（29）：12123-12128 al. A synthetic consensus anti⁃spike protein DNA vaccine
［32］ DUAN J，YAN X，GUO X，et al. A human SARS⁃CoV neu⁃ induces protective immunity against Middle East respira⁃
tralizing antibody against epitope on S2 protein［J］. Bio⁃ tory syndrome coronavirus in nonhuman primates［J］. Sci
chem Biophys Res Commun，2005，333（1）：186-193 Transl Med，2015，7（301）：301ra132
［33］ TRAGGIAI E，BECKER S，SUBBARAO K，et al. An effi⁃ ［45］ ZHANG N，JIANG S，DU L. Current advancements and
cient method to make human monoclonal antibodies from potential strategies in the development of MERS⁃CoV vac⁃
memory B cells：potent neutralization of SARS coronavirus cines［J］. Expert Rev Vaccines，2014，13（6）：761-774
［J］. Nat Med，2004，10（8）：871-875 ［46］ HE Y，LI J，HECK S，et al. Antigenic and immunogenic
［34］ BROUWER P M，CANIELS T G，STRATEN K D，et al. characterization of recombinant baculovirus⁃expressed se⁃
Potent neutralizing antibodies from COVID ⁃ 19 patients vere acute respiratory syndrome coronavirus spike pro⁃
define multiple targets of vulnerability［J］. Science，2020， tein：implication for vaccine design［J］. J Virol，2006，80
369（6504）：643-650 （12）：5757-5767
［35］ GRAND R L，MAISONNASSE P，ALDON Y，et al. CO⁃ ［47］ LI J，ULITZKY L，SILBERSTEIN E，et al. Immunogenici⁃
VA1⁃18 neutralizing antibody protects against SARS⁃CoV ty and protection efficacy of monomeric and trimeric re⁃
⁃ 2 in three preclinical models［J］. ResSq，2021.doi： combinant SARS coronavirus spike protein subunit vac⁃
10.21203/rs.3.rs⁃235272/v1 cine candidates［J］. Viral Immunol，2013，26（2）：126-
［36］ BAUM A，FULTON B O，WLOGA E，et al. Antibody cock⁃ 132
tail to SARS⁃CoV⁃2 spike protein prevents rapid mutation⁃ ［48］ JAUME M，YIP M S，KAM Y W，et al. SARS CoV subunit
al escape seen with individual antibodies［J］. Science， vaccine：antibody ⁃ mediatedneutralisation and enhance⁃
2020，369（656）：1014-1018 ment［J］. Hong Kong Med J，2012，18（Suppl 2）：31-36
［37］ HANSEN J，BAUM A，PASCAL K E，et al. Studies in hu⁃ ［49］ KAM Y W，KIEN F，ROBERTS A，et al. Antibodies
manized mice and convalescent humans yield a SARS ⁃ against trimeric S glycoprotein protect hamsters against
CoV⁃2 antibody cocktail［J］. Science，2020，369（656）： SARS⁃CoV challenge despite their capacity to mediate Fc⁃
1010-1014 gammaRII⁃dependent entry into B cells in vitro［J］. Vac⁃
［38］ WEINREICH D M，SIVAPALASINGAM S，NORTON T， cine，2007，25（4）：729-740
et al. REGN⁃COV2，a neutralizing antibody cocktail，in ［50］ HE Y，ZHOU Y，LIU S，et al. Receptor⁃binding domain of
outpatients with covid⁃19［J］. N Engl J Med，2021，384 SARS⁃CoV spike protein induces highly potent neutraliz⁃
（3）：238-251 ing antibodies：implication for developing subunit vaccine
［39］ SAHIN U，MUIK A，DERHOVANESSIAN E，et al. COV⁃ ［J］. BiochemBiophys Res Commun，2004，324（2）：773-
ID⁃19 vaccine BNT162b1 elicits human antibody and T 781
（H）1 T cell responses［J］. Nature，2020，586（7830）： ［51］ DU L，ZHAO G，HE Y，et al. Receptor⁃binding domain of

594-599 SARS⁃CoV spike protein induces long⁃term protective im⁃
［40］ SONG F，FUX R，PROVACIA L B，et al. Middle East re⁃ munity in an animal model［J］. Vaccine，2007，25（15）：
spiratory syndrome coronavirus spike protein delivered by 2832-2838
modified vaccinia virus Ankara efficiently induces virus⁃ ［52］ DU L，ZHAO G，LI L，et al. Antigenicity and immunoge⁃
neutralizing antibodies［J］. J Virol，2013，87（21）： nicity of SARS⁃CoV S protein receptor⁃binding domain